Q-omics provides the consensus-scored RHBDL2 profile across patient tissues and cancer cell-line models. RHBDL2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RHBDL2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, RHBDL2 RNA expression shows 18,173 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where RHBDL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHBDL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHBDL2 survival associations across molecular data types. RHBDL2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHBDL2 RNA expression–survival associations across cancer types. High RHBDL2 expression shows unfavorable associations in KIRC, ACC, UVM, KIRP, LGG and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RHBDL2 RNA expression.
This table summarizes RHBDL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RHBDL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHBDL2 shows lower tumor expression in COAD and KICH and higher tumor expression in LUAD, KIRC, THCA and KIRP. The COAD box plot shows higher RHBDL2 RNA expression in normal versus tumor tissue (log2 FC = −2.105, t-test p < 0.001).
This table shows molecular features associated with RHBDL2 in patient tissues and cancer cell lines. In patient samples, RHBDL2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RHBDL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
